

## AT A GLANCE

NASDAQ: GILD  
 Founded: 1987  
 HQ: Foster City, CA

**\$104.99B**  
 Market Cap  
 (as of 2/6/2018)



~10,000  
 Employees



Presence in  
**>35** Countries  
 across  
**6** Continents



**4** Primary Therapeutic  
 Areas of Focus:

- Antiviral
- Liver Disease
- Oncology
- Inflammation

### 4Q17 FINANCIALS

---

PRODUCT REVENUE

**\$5.8B**

FY: \$25.7B

NON-GAAP EPS

**\$1.78**


FY: \$8.84

OPERATING CASH FLOW

**\$2.75B**

FY: \$11.9B

## SELECTED PIPELINE PRODUCT CANDIDATES



## COMMERCIAL PORTFOLIO HIGHLIGHTS

### Human Immunodeficiency Virus (HIV)

Treatment:



Prevention:



### Hepatitis C Virus (HCV)



### Hepatitis B Virus (HBV)



### Hematology / Oncology



A GILEAD Company

"Cell Design Labs' talented team of cell biology experts will augment and accelerate our work to bring forward new generations of CAR T and TCR therapies, building on our acquisition of Kite earlier this year and our efforts to improve care for people with advanced cancers."

John F. Milligan, PhD  
 Gilead's President and Chief Executive Officer

## ANALYST COVERAGE

Argus, Atlantic Equities, Baird, BofA Merrill Lynch, Barclays, BMO, Citi, Cowen & Company, Credit Suisse, Deutsche Bank, Evercore ISI, Goldman Sachs, Guggenheim Securities, Jefferies, JPMorgan, Leerink Partners, Maxim Group, Mizuho, Morgan Stanley, Morningstar, Needham, Oppenheimer, RBC, Standard and Poors, UBS, Wells Fargo